ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have been given a consensus recommendation of “Moderate Buy” by the five ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $4.50.

ALXO has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of ALX Oncology in a report on Tuesday, March 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of ALX Oncology in a report on Wednesday, January 21st. UBS Group started coverage on shares of ALX Oncology in a research report on Friday, March 6th. They set a “buy” rating and a $6.00 price target for the company. Wall Street Zen raised shares of ALX Oncology from a “sell” rating to a “hold” rating in a report on Monday, December 22nd. Finally, Piper Sandler increased their price objective on ALX Oncology from $3.00 to $4.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th.

Insider Buying and Selling

In other ALX Oncology news, Director Corey S. Goodman bought 3,184,713 shares of the firm’s stock in a transaction on Monday, February 2nd. The shares were acquired at an average cost of $1.57 per share, for a total transaction of $4,999,999.41. Following the purchase, the director directly owned 8,453,038 shares of the company’s stock, valued at $13,271,269.66. The trade was a 60.45% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 21.00% of the stock is currently owned by insiders.

Institutional Trading of ALX Oncology

Large investors have recently modified their holdings of the business. Ameriprise Financial Inc. bought a new position in shares of ALX Oncology in the 3rd quarter worth $1,195,000. Two Sigma Investments LP raised its position in shares of ALX Oncology by 26.9% during the 3rd quarter. Two Sigma Investments LP now owns 606,671 shares of the company’s stock valued at $1,110,000 after buying an additional 128,737 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of ALX Oncology by 16.8% during the 1st quarter. Acadian Asset Management LLC now owns 1,296,331 shares of the company’s stock worth $806,000 after acquiring an additional 186,883 shares during the last quarter. Renaissance Technologies LLC grew its position in ALX Oncology by 157.2% in the fourth quarter. Renaissance Technologies LLC now owns 423,099 shares of the company’s stock worth $478,000 after acquiring an additional 258,600 shares in the last quarter. Finally, State Street Corp grew its position in ALX Oncology by 11.0% in the fourth quarter. State Street Corp now owns 124,228 shares of the company’s stock worth $140,000 after acquiring an additional 12,300 shares in the last quarter. Institutional investors own 97.97% of the company’s stock.

ALX Oncology Price Performance

Shares of NASDAQ ALXO opened at $2.17 on Wednesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.07 and a current ratio of 2.07. ALX Oncology has a fifty-two week low of $0.40 and a fifty-two week high of $2.66. The stock has a market cap of $117.66 million, a PE ratio of -1.14 and a beta of 0.47. The stock has a fifty day moving average of $1.91 and a 200-day moving average of $1.60.

ALX Oncology (NASDAQ:ALXO) last issued its quarterly earnings data on Monday, March 9th. The company reported ($0.42) earnings per share (EPS) for the quarter. Equities research analysts anticipate that ALX Oncology will post -2.76 earnings per share for the current year.

ALX Oncology Company Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.